-3.65%07-07“An Anthropic long-term deal on top of HBM sold out through 2027 — this 20% pullback is shaking out tourists, not rewriting the script. Above $880, sitting tight beats fidgeting”
Score8/10RSI(14) 47.0Off 6/25 all-time high -21.8%WSB rank #1 (mentions cooling 695→480)New catalyst Multi-year Anthropic AI memory deal
Technicals — Up 1.1% to $948.80, a second straight day of stabilization after a 21.8% retreat from the 6/25 all-time high of $1,213. RSI at 47 is neutral, price holds above the 50-day ($880), and the -12.3% week has digested the Samsung-triggered sector panic. $880 is the trend line in the sand; the structure above it is intact.
Fundamentals — Record FQ3 revenue of $41.46B, HBM sold out through 2027 and $100B of contracted multi-year revenue. A new multi-year pact makes Micron the first-choice memory supplier for Anthropic's advanced AI systems, with HBM co-development. The shortage narrative is fully intact; the one variable is fund rotation once SK Hynix lists on 7/10 and offers a direct valuation comp.
News — MU steadied with the broad chip rebound on 7/8. SK Hynix's Nasdaq debut on 7/10 is the week's biggest memory event — a direct comp could compress multiples or confirm the sector's scarcity value. Analysts broadly read the pullback as a healthy shakeout after blowout earnings.
Short-term · 1–3 weeks
LongBullish
Holding: the shortage script is unchanged and the Anthropic deal adds certainty. The $880 (50-day) hard stop stands; if SK Hynix's debut week rattles memory names, respond with stop discipline rather than prediction.
Entry Hold within $900–950; a retest of the 50-day (~$880) is the add-watch zoneStop $880Target $1150
Long-term · months+
Accumulate
HBM is AI compute's first bottleneck. With capacity locked to 2027, $100B contracted revenue as a floor, and deep Anthropic alignment, Micron is the purest vehicle for the memory supercycle.
SK Hynix's listing siphons flows via direct comparison
Peak-cycle capex and an eventual supply response
Rising large-customer concentration
Signal BacktestCumulative -3.65%price itself -8.09%
07-07Long$984.75 → open → $948.8-3.65%
Community Voices
WSB · Mentions cooled from 695 to 480 yet still #1 — peak noise usually marks the top; quiet is where trends liveOriginal ↗
Institutional Views
华尔街共识 · 53 analysts, average target $1,576 (+66% vs. spot), 1.14 rating — near strong buy
TradingKey · The Anthropic deal locks in multi-year AI memory demand; the trendline held after a 22% pullbackSource ↗
+4.77%07-04“Bears spent three days on the China-substitution story, then Beijing turned around and cleared H200 buys for Alibaba and ByteDance — the rebuttal arrived faster than earnings. Above the 200-day, don't moonlight as a bear”
Score8/10RSI(14) 51.0Day move +3.7%Kyber delay report Denied — on scheduleChina H200 Beijing may allow limited purchases
Technicals — Up 3.7% to $204.12, a fifth day holding the 200-day ($191.4), RSI repaired to a neutral 51. After shedding a trillion dollars of market cap from the May peak, relative strength has clearly turned this week; the 50-day ($209.5) is the overhead test — clearing it opens the recovery trade.
Fundamentals — Both bear cases got dismantled in one session: the company denied reports of a Kyber NVL144 slip to 2028, and Beijing is reportedly set to let Alibaba, ByteDance and DeepSeek buy limited H200 quantities — the China story inflecting up from 'zeroed out.' Goldman calls 21.7x forward earnings 'compelling.'
News — Shares rallied 3.8% intraday on 7/8 on the Kyber denial and H200 access reports, after two sessions of selling on Samsung's results and DeepSeek chip rumors. This bounce is the first forceful rebuttal to the 'AI capex peak' thesis.
Short-term · 1–3 weeks
LongBullish
Holding: five closes above the 200-day plus two falsified bear cases raise the odds of trend repair. Stop at $188 (a half-ATR buffer under the 200-day), to be raised on a break of $210.
Entry Hold $195–205; a reclaim of the 50-day ($210) confirms the repairStop $188Target $230
Long-term · months+
Accumulate
Still the toll collector of the AI compute arms race, with China's marginal thaw as a free option; a year of sideways action has digested the valuation, and 21.7x forward is a three-year low.
A real AI capex slowdown means a double derating
Long-run substitution from DeepSeek-style in-house silicon
Policy whiplash — H200 access could be revoked anytime
Signal BacktestCumulative +4.77%price itself +3.31%profitable since 07-07
07-04Long$194.83 → open → $204.12+4.77%
Community Voices
WSB · Mentions rose 222→267 against the tape, rank #3 — bears finished the China story just as bulls got the approval headline; sentiment turned half a day before the newsOriginal ↗
Institutional Views
华尔街共识 · 66 analysts, average target $313 (+54% vs. spot), 1.13 — strong-buy territory
Goldman Sachs · Calls 21.7x forward P/E 'compelling'; reiterated Buy after the Kyber delay was deniedSource ↗
-6.12%07-07“Deliveries smashed estimates and robotaxis went live in Miami — the story is mid-delivery. $390 is the bulls' last stitch of dignity: if it breaks, run first, analyze later”
Score7/10RSI(14) 47.1Q2 deliveries 480,126 (vs. 406k est.)Robotaxi Live in MiamiEarnings 7/22
Technicals — Down 2.2% to $394.06, a third day pinned in the $390–402 range, sitting right atop yesterday's $390 stop. RSI 47 is neutral, the 20-day ($399) caps upside, the 200-day sits at $418. A directional resolution is near, with 7/22 earnings as the pricing event.
Fundamentals — Q2 deliveries of 480,126 crushed the 406k estimate, with Deutsche Bank pegging Europe at +40% YoY as the engine; robotaxi service went live in Miami after July 4th, moving autonomy from slide decks to an operating line. The bear case is valuation and Q2 margins — 7/22 settles it.
News — The stock fell 2.2% despite the delivery beat — read either as 'good news spent' or pre-earnings de-risking. Motley Fool ran dueling bull and bear pieces the same day; the disagreement has rarely been this evenly matched.
Short-term · 1–2 weeks
LongLean bullish
Holding: delivery and robotaxi catalysts are landing, but consensus targets hugging spot mean upside requires estimate revisions. The $390 hard stop is body armor; failure to reclaim the 20-day ($399) pre-earnings would flag fading momentum.
Entry Hold, no adds; no lingering below $390Stop $390Target $430
Long-term · months+
Neutral
Robotaxi and FSD define the second growth curve, and the delivery rebound proves the base business has stabilized; but the price already embeds a lot of autonomy optionality, leaving a thin margin of safety.
A Q2 margin miss would force the delivery beat to be repriced
Robotaxi regulatory and safety-incident risk
Durability of the European demand surge is unproven
Signal BacktestCumulative -6.12%price itself -7.35%
07-07Long$419.77 → open → $394.06-6.12%
Community Voices
StockTwits · Delivery bulls and valuation bears talk past each other; after the Miami launch it all rides on the night of 7/22 — less a debate than a duel of faithsOriginal ↗
Institutional Views
华尔街共识 · 50 analysts, average target $404 (just +2.6% vs. spot), 1.77 rating — the Street is notably cooler than retail
Deutsche Bank · Europe Q2 deliveries up ~40% YoY — the main source of the beatSource ↗
New today“Morgan Stanley's downgrade hit the GLP-1 nerve, and what kills a momentum stock isn't the drop — it's the story going stale. Take the small loss and leave; don't stay to argue with weight-loss drugs”
Score5/10RSI(14) 53.8Day move -6.3%Morgan Stanley Cut to EqualweightPosition closed Stopped out ~-5.7%
Technicals — Down 6.3% to $205.84, a single-day break of the consolidation shelf above the 20-day on heavier volume. Price technically holds the 50-day ($201.4), but one long red candle wrecked the momentum structure, with RSI dumping from 60+ to 53.8.
Fundamentals — Morgan Stanley's downgrade lands a triple hit: capped near-term margin growth, Philips potentially re-entering the US PAP market, and GLP-1 drugs structurally eroding sleep-apnea treatment demand. The first two are cyclical; the third is structural — and the root of a year of multiple compression. A $1.25M CEO share sale adds to the shadow.
News — Fell 6.3% on 7/8 on the Morgan Stanley downgrade, leading med-tech lower. The stock is down 23% over 12 months — the GLP-1 erosion thesis returns every few months to harvest momentum buyers.
Short-term · 1–3 weeks
NeutralSidelines
Stopped out (~-5.7%): the entry thesis was momentum continuation above the moving averages, and a 6.3% downgrade candle shattered it in one session. GLP-1 is a structural overhang — not something worth testing with open risk.
Entry Position closed; no re-entry consideration unless the setup rebuilds — and none below $195Stop —Target —
Long-term · months+
Neutral
Sleep-apnea penetration remains low and the device-plus-consumables model throws off quality cash flow, but GLP-1's erosion of the demand curve can't be falsified; a re-rating needs successive quarters proving demand resilience.
Expanding GLP-1 indications directly shrink the patient pool
A Philips US comeback triggers price competition
FX and reimbursement policy noise
Community Voices
StockTwits · Yesterday the board counted gains off the 52-week low; today everyone asks how much demand GLP-1 really eats. The question never changed — who's asking didOriginal ↗
Institutional Views
华尔街共识 · 30 analysts average $270 (+31% vs. spot), but the Morgan Stanley cut cracks the consensus
Morgan Stanley · Cut to Equalweight: margin pressure, Philips re-entry risk, long-run GLP-1 demand erosionSource ↗
